enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 42.47% | 9.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.40% | 2.51% | |||
| Operating Income | -6.40% | -2.51% | |||
| Income Before Tax | -7.52% | -1.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.52% | -1.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.52% | -1.60% | |||
| EBIT | -6.40% | -2.51% | |||
| EBITDA | -6.44% | -2.56% | |||
| EPS Basic | -7.52% | 1.99% | |||
| Normalized Basic EPS | -7.53% | 0.37% | |||
| EPS Diluted | -7.52% | 1.99% | |||
| Normalized Diluted EPS | -7.53% | 0.37% | |||
| Average Basic Shares Outstanding | 0.01% | 3.66% | |||
| Average Diluted Shares Outstanding | 0.01% | 3.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||